Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds

Table of Contents

March 1, 2021; Volume 62,Issue 3

This Month in JNM

  • You have access
    This Month in JNM
    Journal of Nuclear Medicine March 1, 2021, 62 (3) 10A;

Discussions with Leaders

  • You have access
    A Conversation Between Hong Wu and Johannes Czernin
    Hong Wu and Johannes Czernin
    Journal of Nuclear Medicine March 1, 2021, 62 (3) 293-295; DOI: https://doi.org/10.2967/jnumed.121.262007

The State of the Art

  • You have access
    FAPI PET/CT: Will It End the Hegemony of 18F-FDG in Oncology?
    Rodney J. Hicks, Peter J. Roselt, Kumarswamy G. Kallur, Richard W. Tothill and Linda Mileshkin
    Journal of Nuclear Medicine March 1, 2021, 62 (3) 296-302; DOI: https://doi.org/10.2967/jnumed.120.256271

Hot Topics

  • You have access
    Phantom Preparation Using a Dilution Technique
    Martin A. Lodge
    Journal of Nuclear Medicine March 1, 2021, 62 (3) 303; DOI: https://doi.org/10.2967/jnumed.120.257097

Continuing Education

  • You have access
    The Role of Nuclear Medicine in the Clinical Management of Benign Thyroid Disorders, Part 1: Hyperthyroidism
    Giuliano Mariani, Massimo Tonacchera, Mariano Grosso, Francesca Orsolini, Paolo Vitti and H. William Strauss
    Journal of Nuclear Medicine March 1, 2021, 62 (3) 304-312; DOI: https://doi.org/10.2967/jnumed.120.243170

Focus on Molecular Imaging

  • You have access
    Advances in Receptor-Targeted Radiolabeled Peptides for Melanoma Imaging and Therapy
    Yubin Miao and Thomas P. Quinn
    Journal of Nuclear Medicine March 1, 2021, 62 (3) 313-318; DOI: https://doi.org/10.2967/jnumed.120.243840

Oncology

  • Clinical

    • Voxelwise and Patientwise Correlation of <sup>18</sup>F-FDOPA PET, Relative Cerebral Blood Volume, and Apparent Diffusion Coefficient in Treatment-Naïve Diffuse Gliomas with Different Molecular Subtypes
      You have access
      Voxelwise and Patientwise Correlation of 18F-FDOPA PET, Relative Cerebral Blood Volume, and Apparent Diffusion Coefficient in Treatment-Naïve Diffuse Gliomas with Different Molecular Subtypes
      Hiroyuki Tatekawa, Akifumi Hagiwara, Jingwen Yao, Talia C. Oughourlian, Issei Ueda, Hiroyuki Uetani, Catalina Raymond, Albert Lai, Timothy F. Cloughesy, Phioanh L. Nghiemphu, Linda M. Liau, Whitney B. Pope, Noriko Salamon and Benjamin M. Ellingson
      Journal of Nuclear Medicine March 1, 2021, 62 (3) 319-325; DOI: https://doi.org/10.2967/jnumed.120.247411
    • Head-to-Head Evaluation of <sup>18</sup>F-FES and <sup>18</sup>F-FDG PET/CT in Metastatic Invasive Lobular Breast Cancer
      You have access
      Head-to-Head Evaluation of 18F-FES and 18F-FDG PET/CT in Metastatic Invasive Lobular Breast Cancer
      Gary A. Ulaner, Komal Jhaveri, Sarat Chandarlapaty, Vaios Hatzoglou, Christopher C. Riedl, Jason S. Lewis and Audrey Mauguen
      Journal of Nuclear Medicine March 1, 2021, 62 (3) 326-331; DOI: https://doi.org/10.2967/jnumed.120.247882
    • Automated Segmentation of Baseline Metabolic Total Tumor Burden in Diffuse Large B-Cell Lymphoma: Which Method Is Most Successful? A Study on Behalf of the PETRA Consortium
      You have access
      Automated Segmentation of Baseline Metabolic Total Tumor Burden in Diffuse Large B-Cell Lymphoma: Which Method Is Most Successful? A Study on Behalf of the PETRA Consortium
      Sally F. Barrington, Ben G.J.C. Zwezerijnen, Henrica C.W. de Vet, Martijn W. Heymans, N. George Mikhaeel, Coreline N. Burggraaff, Jakoba J. Eertink, Lucy C. Pike, Otto S. Hoekstra, Josée M. Zijlstra and Ronald Boellaard
      Journal of Nuclear Medicine March 1, 2021, 62 (3) 332-337; DOI: https://doi.org/10.2967/jnumed.119.238923
    • You have access
      Comparison of Interim PET Response to Second-Line Versus First-Line Treatment in Classic Hodgkin Lymphoma: Contribution to the Development of Response Criteria for Relapsed or Progressive Disease
      Regine Kluge, Tim Wittig, Thomas W. Georgi, Lars Kurch, Osama Sabri, W. Hamish Wallace, Tomasz Klekawka, Ana Fernández-Teijeiro, Francesco Ceppi, Jonas Karlén, Jane Pears, Michaela Cepelová, Alexander Fosså, Auke Beishuizen, Lisa Lyngsie Hjalgrim, Dieter Körholz, Christine Mauz-Körholz and Dirk Hasenclever
      Journal of Nuclear Medicine March 1, 2021, 62 (3) 338-341; DOI: https://doi.org/10.2967/jnumed.120.247924
    • You have access
      Fluorescence-Guided Visualization of Soft-Tissue Sarcomas by Targeting Vascular Endothelial Growth Factor A: A Phase 1 Single-Center Clinical Trial
      Pieter J. Steinkamp, Bobby K. Pranger, Mei-Fang Li, Matthijs D. Linssen, Floris J. Voskuil, Lukas B. Been, Barbara L. van Leeuwen, Albert J.H. Suurmeijer, Wouter B. Nagengast, Schelto Kruijff, Robert J. van Ginkel and Gooitzen M. van Dam
      Journal of Nuclear Medicine March 1, 2021, 62 (3) 342-347; DOI: https://doi.org/10.2967/jnumed.120.245696
    • You have access
      Evaluation of 18F-FDG PET and DWI Datasets for Predicting Therapy Response of Soft-Tissue Sarcomas Under Neoadjuvant Isolated Limb Perfusion
      Michal Chodyla, Aydin Demircioglu, Benedikt M. Schaarschmidt, Stefanie Bertram, Nils Martin Bruckmann, Jennifer Haferkamp, Yan Li, Sebastian Bauer, Lars Podleska, Christoph Rischpler, Michael Forsting, Ken Herrmann, Lale Umutlu and Johannes Grueneisen
      Journal of Nuclear Medicine March 1, 2021, 62 (3) 348-353; DOI: https://doi.org/10.2967/jnumed.120.248260
    • FEATURED CLINICAL INVESTIGATION ARTICLE

      • Urokinase-Type Plasminogen Activator Receptor (uPAR) PET/MRI of Prostate Cancer for Noninvasive Evaluation of Aggressiveness: Comparison with Gleason Score in a Prospective Phase 2 Clinical Trial
        You have access
        Urokinase-Type Plasminogen Activator Receptor (uPAR) PET/MRI of Prostate Cancer for Noninvasive Evaluation of Aggressiveness: Comparison with Gleason Score in a Prospective Phase 2 Clinical Trial
        Marie Øbro Fosbøl, Sorel Kurbegovic, Helle Hjorth Johannesen, Martin Andreas Røder, Adam Espe Hansen, Jann Mortensen, Annika Loft, Peter Meidahl Petersen, Jacob Madsen, Klaus Brasso and Andreas Kjaer
        Journal of Nuclear Medicine March 1, 2021, 62 (3) 354-359; DOI: https://doi.org/10.2967/jnumed.120.248120
    • You have access
      A Microdosing Study with 99mTc-PHC-102 for the SPECT/CT Imaging of Primary and Metastatic Lesions in Renal Cell Carcinoma Patients
      Oana C. Kulterer, Sarah Pfaff, Wolfgang Wadsak, Nathalie Garstka, Mesut Remzi, Chrysoula Vraka, Lukas Nics, Markus Mitterhauser, Franziska Bootz, Samuele Cazzamalli, Nikolaus Krall, Dario Neri and Alexander R. Haug
      Journal of Nuclear Medicine March 1, 2021, 62 (3) 360-365; DOI: https://doi.org/10.2967/jnumed.120.245530
  • Basic

    • FEATURED ARTICLE OF THE MONTH

      • Immuno-PET Detects Changes in Multi-RTK Tumor Cell Expression Levels in Response to Targeted Kinase Inhibition
        Open Access
        Immuno-PET Detects Changes in Multi-RTK Tumor Cell Expression Levels in Response to Targeted Kinase Inhibition
        Patricia M.R. Pereira, Jalen Norfleet, Jason S. Lewis and Freddy E. Escorcia
        Journal of Nuclear Medicine March 1, 2021, 62 (3) 366-371; DOI: https://doi.org/10.2967/jnumed.120.244897
    • Noninvasive Evaluation of CD20 Expression Using <sup>64</sup>Cu-Labeled F(ab′)<sub>2</sub> Fragments of Obinutuzumab in Lymphoma
      You have access
      Noninvasive Evaluation of CD20 Expression Using 64Cu-Labeled F(ab′)2 Fragments of Obinutuzumab in Lymphoma
      Lei Kang, Cuicui Li, Zachary T. Rosenkrans, Jonathan W. Engle, Rongfu Wang, Dawei Jiang, Xiaojie Xu and Weibo Cai
      Journal of Nuclear Medicine March 1, 2021, 62 (3) 372-378; DOI: https://doi.org/10.2967/jnumed.120.246595

Theranostics

  • Clinical

    • You have access
      Dissimilar DNA Damage to Blood Lymphocytes After 177Lu-Labeled DOTATOC or Prostate-Specific Membrane Antigen Therapy
      Philipp Ritt, Camille Jobic, Michael Beck, Christian Schmidkonz, Torsten Kuwert, Michael Uder and Michael Brand
      Journal of Nuclear Medicine March 1, 2021, 62 (3) 379-385; DOI: https://doi.org/10.2967/jnumed.120.243782
    • You have access
      Peptide Receptor Radionuclide Therapy of Late-Stage Neuroendocrine Tumor Patients with Multiple Cycles of 177Lu-DOTA-EB-TATE
      Qingxing Liu, Jie Zang, Huimin Sui, Jiakun Ren, Hua Guo, Hao Wang, Rongxi Wang, Orit Jacobson, Jingjing Zhang, Yuejuan Cheng, Zhaohui Zhu and Xiaoyuan Chen
      Journal of Nuclear Medicine March 1, 2021, 62 (3) 386-392; DOI: https://doi.org/10.2967/jnumed.120.248658
  • Basic

    • Multimodal Imaging of 2-Cycle PRRT with <sup>177</sup>Lu-DOTA-JR11 and <sup>177</sup>Lu-DOTATOC in an Orthotopic Neuroendocrine Xenograft Tumor Mouse Model
      You have access
      Multimodal Imaging of 2-Cycle PRRT with 177Lu-DOTA-JR11 and 177Lu-DOTATOC in an Orthotopic Neuroendocrine Xenograft Tumor Mouse Model
      Jakob Albrecht, Samantha Exner, Carsten Grötzinger, Sonal Prasad, Frank Konietschke, Nicola Beindorff, Anja A. Kühl, Vikas Prasad, Winfried Brenner and Eva J. Koziolek
      Journal of Nuclear Medicine March 1, 2021, 62 (3) 393-398; DOI: https://doi.org/10.2967/jnumed.120.250274

Pulmonary

  • Clinical

    • You have access
      Diagnostic Performance of Pulmonary Embolism Imaging in Patients with History of Asthma
      Matthew S. Lazarus, Yoel Kim, Bertin Mathai, Jeffrey M. Levsky, Leonard M. Freeman, Linda B. Haramati and Renee M. Moadel
      Journal of Nuclear Medicine March 1, 2021, 62 (3) 399-404; DOI: https://doi.org/10.2967/jnumed.120.242776
    • You have access
      PET Imaging Reveals Early Pulmonary Perfusion Abnormalities in HIV Infection Similar to Smoking
      Puja Kohli, Vanessa J. Kelly, Kathryn A. Hibbert, Björn Corleis, Mamary Kone, Josalyn L. Cho, Doreen DeFaria-Yeh, Douglas S. Kwon, Benjamin D. Medoff, R. Scott Harris and Tilo Winkler
      Journal of Nuclear Medicine March 1, 2021, 62 (3) 405-411; DOI: https://doi.org/10.2967/jnumed.120.245977

Neurology

  • Clinical

    • Nondisplaceable Binding Is a Potential Confounding Factor in <sup>11</sup>C-PBR28 Translocator Protein PET Studies
      You have access
      Nondisplaceable Binding Is a Potential Confounding Factor in 11C-PBR28 Translocator Protein PET Studies
      Gjertrud L. Laurell, Pontus Plavén-Sigray, Aurelija Jucaite, Andrea Varrone, Kelly P. Cosgrove, Claus Svarer, Gitte M. Knudsen, Karolinska Schizophrenia Project Consortium, R. Todd Ogden, Francesca Zanderigo, Simon Cervenka, Ansel T. Hillmer and Martin Schain
      Journal of Nuclear Medicine March 1, 2021, 62 (3) 412-417; DOI: https://doi.org/10.2967/jnumed.120.243717
    • BRIEF COMMUNICATION

      • Simplified Quantification of <sup>11</sup>C-UCB-J PET Evaluated in a Large Human Cohort
        You have access
        Simplified Quantification of 11C-UCB-J PET Evaluated in a Large Human Cohort
        Mika Naganawa, Jean-Dominique Gallezot, Sjoerd J. Finnema, David Matuskey, Adam Mecca, Nabeel B. Nabulsi, David Labaree, Jim Ropchan, Robert T. Malison, Deepak Cyril D’Souza, Irina Esterlis, Kamil Detyniecki, Christopher H. van Dyck, Yiyun Huang and Richard E. Carson
        Journal of Nuclear Medicine March 1, 2021, 62 (3) 418-421; DOI: https://doi.org/10.2967/jnumed.120.243949

Radiopharmaceuticals

  • You have access
    Global Issues of Radiopharmaceutical Access and Availability: A Nuclear Medicine Global Initiative Project
    Cathy S. Cutler, Elizabeth Bailey, Vijay Kumar, Sally W. Schwarz, Hee-Seung Bom, Jun Hatazawa, Diana Paez, Pilar Orellana, Lizette Louw, Fernando Mut, Hiroki Kato, Arturo Chiti, Savvas Frangos, Frederic Fahey, Gary Dillehay, Seung J. Oh, Dong S. Lee, Sze-Ting Lee, Rodolfo Nunez-Miller, Guru Bandhopadhyaya, Prasanta K. Pradhan and Andrew M. Scott
    Journal of Nuclear Medicine March 1, 2021, 62 (3) 422-430; DOI: https://doi.org/10.2967/jnumed.120.247197

Errata

  • You have access
    Erratum
    Journal of Nuclear Medicine March 1, 2021, 62 (3) 404;

Letters to the Editor

  • You have access
    Automated Segmentation of TMTV in DLBCL Patients: What About Method Measurement Uncertainty?
    Eric Laffon and Roger Marthan
    Journal of Nuclear Medicine March 1, 2021, 62 (3) 431; DOI: https://doi.org/10.2967/jnumed.120.256214
  • You have access
    Reply: Automated Segmentation of TMTV in DLBCL Patients: What About Method Measurement Uncertainty?
    Sally F. Barrington, Ben G.J.C. Zwezerijnen, Henrica C.W. de Vet, Martijn W. Heymans and Ronald Boellaard
    Journal of Nuclear Medicine March 1, 2021, 62 (3) 432; DOI: https://doi.org/10.2967/jnumed.120.257030
  • You have access
    Data-Driven Motion Correction in Clinical PET: A Joint Accomplishment of Creative Academia and Industry
    Adam L. Kesner
    Journal of Nuclear Medicine March 1, 2021, 62 (3) 433-434; DOI: https://doi.org/10.2967/jnumed.120.248187
  • You have access
    Reply: Data-Driven Motion Correction in Clinical PET: A Joint Accomplishment of Creative Academia and Industry
    Matthew D. Walker, Kevin M. Bradley and Daniel R. McGowan
    Journal of Nuclear Medicine March 1, 2021, 62 (3) 435; DOI: https://doi.org/10.2967/jnumed.120.257022

SNMMI Newsline

  • You have access
    SNMMI Newsline
    Journal of Nuclear Medicine March 1, 2021, 62 (3) 11N-19N;
  • You have access
    SNMMI Mid-Winter and ACNM Annual Meeting
    Journal of Nuclear Medicine March 1, 2021, 62 (3) 11N;
  • You have access
    SNMMI 2021 Annual Meeting
    Alan Packard and Tina M. Buehner
    Journal of Nuclear Medicine March 1, 2021, 62 (3) 11N;
  • You have access
    American Cancer Society Cancer Statistics 2021 Report
    Journal of Nuclear Medicine March 1, 2021, 62 (3) 12N;
  • You have access
    Retired ABNM Diplomates
    George M. Segall
    Journal of Nuclear Medicine March 1, 2021, 62 (3) 13N;
  • You have access
    In Memoriam: Anna Celler, PhD, 1951–2020
    Arman Rahmim, Carlos Uribe, Alex MacKay and Glenn Wells
    Journal of Nuclear Medicine March 1, 2021, 62 (3) 14N;
  • You have access
    SNMMI Leadership Update: Advocating for Our Field
    Alan B. Packard
    Journal of Nuclear Medicine March 1, 2021, 62 (3) 15N;
  • You have access
    Newsbriefs
    Journal of Nuclear Medicine March 1, 2021, 62 (3) 16N-18N;
  • You have access
    From the Literature
    Journal of Nuclear Medicine March 1, 2021, 62 (3) 19N-22N;
Back to top
PreviousNext

In this issue

Journal of Nuclear Medicine: 62 (3)
Journal of Nuclear Medicine
Vol. 62, Issue 3
March 1, 2021
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author

Issue highlights

  • Multimodal Imaging of 2-Cycle PRRT with 177Lu-DOTA-JR11 and 177Lu-DOTATOC in an Orthotopic Neuroendocrine Xenograft Tumor Mouse Model
  • Urokinase-Type Plasminogen Activator Receptor (uPAR) PET/MRI of Prostate Cancer for Noninvasive Evaluation of Aggressiveness: Comparison with Gleason Score in a Prospective Phase 2 Clinical Trial
  • Immuno-PET Detects Changes in Multi-RTK Tumor Cell Expression Levels in Response to Targeted Kinase Inhibition
Sign up for alerts

Jump to

  • This Month in JNM
  • Discussions with Leaders
  • The State of the Art
  • Hot Topics
  • Continuing Education
  • Focus on Molecular Imaging
  • Oncology
    • Clinical
      • FEATURED CLINICAL INVESTIGATION ARTICLE
    • Basic
      • FEATURED ARTICLE OF THE MONTH
  • Theranostics
    • Clinical
    • Basic
  • Pulmonary
    • Clinical
  • Neurology
    • Clinical
      • BRIEF COMMUNICATION
  • Radiopharmaceuticals
  • Errata
  • Letters to the Editor
  • SNMMI Newsline
  • Most Cited
  • Most Read
Loading
  • MIRD Pamphlet No. 28, Part 1: MIRDcalc—A Software Tool for Medical Internal Radiation Dosimetry
  • Absorbed Dose–Response Relationship in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with [177Lu]Lu-DOTATATE: One Step Closer to Personalized Medicine
  • Prediction of 177Lu-DOTATATE PRRT Outcome Using Multimodality Imaging in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Results from a Prospective Phase II LUMEN Study
  • Renal and Multiorgan Safety of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer in the VISION Dosimetry Substudy
  • High-Temporal-Resolution Lung Kinetic Modeling Using Total-Body Dynamic PET with Time-Delay and Dispersion Corrections
More...
SNMMI

© 2025 SNMMI

Powered by HighWire